Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

(2013) J. Lin et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer

(2013) A. Gucalp et al.   CLINICAL CANCER RESEARCH

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer

(2013) John P. Crown et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

(2013) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

(2013) David Cameron et al.   LANCET ONCOLOGY

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Understanding the biology of triple-negative breast cancer

(2012) C. Criscitiello et al.   ANNALS OF ONCOLOGY

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

(2012) Roy RL Bastien et al.   BMC Medical Genomics

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

(2012) V Abkevich et al.   BRITISH JOURNAL OF CANCER

Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome

(2012) Z. C. Wang et al.   CLINICAL CANCER RESEARCH

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

(2012) S. Kummar et al.   CLINICAL CANCER RESEARCH

Targeting Mutant p53 in Human Tumors

(2012) Brian D. Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

(2012) Lisa A. Carey et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequence analysis of mutations and translocations across breast cancer subtypes

(2012) Shantanu Banerji et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

(2012) Marieke Aarts et al.   Cancer Discovery

Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents

(2012) Nicolai J. Birkbak et al.   Cancer Discovery

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy

(2011) Sibylle Loibl et al.   BREAST CANCER RESEARCH AND TREATMENT

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

(2011) X. Liu et al.   CLINICAL CANCER RESEARCH

FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo

(2011) Rachel Sharpe et al.   CLINICAL CANCER RESEARCH

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

(2011) Joyce O'Shaughnessy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Triple-Negative Breast Cancer

(2010) Ayca Gucalp et al.   CANCER JOURNAL

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

(2010) M. Graeser et al.   CLINICAL CANCER RESEARCH

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

(2010) N Turner et al.   ONCOGENE

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

(2010) C. G. Fedele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling

(2009) Christina Gewinner et al.   CANCER CELL

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

(2008) C. Desmedt et al.   CLINICAL CANCER RESEARCH

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

(2008) B. Evers et al.   CLINICAL CANCER RESEARCH

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY